NCT01704482

N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement

N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.

Conditions

• Cardiac Surgery for Rheumatic Valvular Heart Disease
• Renal Dysfunction

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
DRUG	placebo

Timeline

• Start date: 2011-02-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-10-11
• Last updated: 2012-10-11

Locations

1 site across 1 country: Egypt